Profile data is unavailable for this security.
About the company
SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing of active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic, and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel, lamotrigine, penciclovir, valaciclovir, and others. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.
- Revenue in INR (TTM)7.68bn
- Net income in INR593.38m
- Incorporated1987
- Employees1.20k
- LocationSMS Pharmaceuticals LtdPlot No.19-III,OP BHARATIYA VIDYA BHAVANPUBLIC ROAD NO 71, JUBILEE HILLSHYDERABAD 500034IndiaIND
- Phone+91 4 066288888
- Fax+91 4 023551401
- Websitehttps://smspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Remus Pharmaceuticals Ltd | 2.12bn | 215.37m | 13.88bn | 48.00 | 63.11 | 15.99 | 51.67 | 6.53 | 37.34 | 37.34 | 374.91 | 147.42 | 1.46 | 7.61 | 3.56 | 44,270,750.00 | 17.80 | -- | 44.48 | -- | 22.67 | -- | 12.22 | -- | 1.12 | 55.56 | 0.0997 | -- | 371.94 | -- | 153.29 | -- | -- | -- |
| Zota Health Care Ltd | 1.98bn | -242.34m | 14.72bn | 445.00 | -- | -- | 3,152.02 | 7.43 | -9.27 | -9.27 | 76.32 | -- | -- | -- | -- | 4,452,605.00 | -- | -1.38 | -- | -1.85 | 49.86 | 35.95 | -12.23 | -1.33 | -- | -2.87 | -- | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Jagsonpal Pharmaceuticals Ltd | 2.27bn | 243.00m | 15.29bn | 1.03k | 64.24 | 7.75 | 53.59 | 6.74 | 8.98 | 8.98 | 83.78 | 74.42 | 0.9703 | 5.13 | 9.92 | 2,213,181.00 | 10.39 | 10.95 | 12.40 | 13.29 | 58.16 | 58.13 | 10.71 | 9.21 | 2.60 | 32.84 | 0.0474 | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
| JG Chemicals Ltd | 7.57bn | 550.05m | 16.18bn | 56.00 | 27.97 | 3.71 | 25.94 | 2.14 | 14.77 | 14.77 | 202.34 | 111.33 | -- | -- | -- | 135,230,700.00 | -- | -- | -- | -- | 17.29 | -- | 7.56 | -- | 11.46 | -- | 0.0281 | -- | -14.90 | -- | -43.84 | -- | -- | -- |
| Sigachi Industries Ltd | 4.36bn | 660.99m | 16.60bn | 991.00 | 29.53 | 3.52 | 21.35 | 3.81 | 1.69 | 1.69 | 11.11 | 14.15 | 0.6266 | 3.01 | 3.27 | 4,396,491.00 | 9.36 | 14.77 | 13.25 | 19.57 | 50.50 | 50.30 | 14.93 | 14.92 | 1.39 | 6.47 | 0.2576 | 1.61 | 32.08 | 25.34 | 31.34 | 24.64 | 70.35 | -- |
| Syncom Formulations (India) Ltd | 3.29bn | 331.47m | 18.97bn | 802.00 | 49.71 | 6.05 | 49.28 | 5.76 | 0.406 | 0.406 | 3.49 | 3.34 | 0.8485 | 6.21 | 3.62 | 4,105,761.00 | 8.54 | 7.50 | 10.99 | 10.23 | 38.49 | 34.10 | 10.07 | 9.38 | 4.09 | 12.05 | 0.0435 | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
| Beta Drugs Ltd | 3.35bn | 410.00m | 19.37bn | 371.00 | 47.25 | 10.71 | 37.95 | 5.79 | 42.65 | 42.65 | 348.21 | 188.13 | 1.26 | 4.04 | 3.74 | 9,022,873.00 | 15.42 | 15.10 | 23.35 | 22.23 | 39.95 | 39.77 | 12.25 | 12.38 | 1.59 | 17.06 | 0.0953 | 0.00 | 30.21 | 35.01 | 18.62 | 35.29 | -10.89 | -- |
| Windlas Biotech Ltd | 6.96bn | 612.28m | 20.04bn | 1.15k | 32.84 | 4.25 | 24.79 | 2.88 | 29.20 | 29.20 | 331.88 | 225.63 | 1.06 | 6.07 | 4.43 | 6,028,180.00 | 9.30 | -- | 13.64 | -- | 37.52 | -- | 8.80 | -- | 1.61 | 30.61 | 0.0388 | -- | 22.97 | -- | 36.51 | -- | -- | -- |
| IOL Chemicals and Pharmaceuticals Ltd. | 20.72bn | 1.19bn | 20.62bn | 2.78k | 17.39 | -- | 11.15 | 0.9953 | 20.20 | 20.20 | 353.05 | -- | -- | -- | -- | 7,461,253.00 | -- | 14.91 | -- | 19.45 | 33.96 | 34.54 | 5.72 | 12.00 | -- | 10.06 | -- | 10.59 | -3.80 | 4.82 | -3.39 | -10.70 | 35.27 | -- |
| Hester Biosciences Ltd | 3.12bn | 234.69m | 20.73bn | 642.00 | 85.90 | 6.87 | 49.22 | 6.64 | 28.37 | 28.37 | 368.62 | 354.81 | 0.4617 | 1.22 | 3.23 | 4,862,882.00 | 3.89 | 6.15 | 4.91 | 7.69 | 71.13 | 66.64 | 8.42 | 12.83 | 1.22 | 2.85 | 0.4371 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
| Amrutanjan Health Care Ltd | 4.38bn | 475.20m | 20.92bn | 635.00 | 44.07 | 7.03 | 38.83 | 4.78 | 16.43 | 16.43 | 151.37 | 103.00 | 1.19 | 6.89 | 12.85 | 6,893,025.00 | 12.88 | 16.22 | 16.48 | 20.12 | 50.03 | 53.09 | 10.86 | 13.23 | 3.62 | 217.88 | 0.0074 | 18.95 | 10.96 | 10.71 | 12.90 | 12.46 | 26.93 | 16.43 |
| SMS Pharmaceuticals Ltd | 7.68bn | 593.38m | 21.20bn | 1.20k | 35.63 | 3.76 | 23.17 | 2.76 | 7.03 | 7.03 | 91.03 | 66.57 | 0.7278 | 1.81 | 4.18 | 6,420,048.00 | 5.55 | 5.43 | 8.40 | 7.33 | 30.10 | 33.30 | 7.62 | 7.87 | 0.7104 | 4.54 | 0.3361 | 6.17 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| Panacea Biotec Ltd | 5.50bn | -148.63m | 24.15bn | 1.15k | -- | 2.90 | 120.96 | 4.39 | -2.46 | -2.46 | 90.20 | 135.98 | 0.4374 | 1.10 | 7.87 | 4,799,546.00 | -1.22 | 10.26 | -1.65 | 16.53 | 63.28 | 50.27 | -2.79 | 24.87 | 1.03 | -13.78 | 0.0254 | 0.00 | 21.57 | 4.13 | 96.47 | -- | 74.65 | -- |
| Themis Medicare Ltd | 4.20bn | 529.90m | 26.34bn | 1.54k | 49.76 | 6.39 | 41.16 | 6.27 | 5.75 | 5.75 | 45.63 | 44.76 | 0.7306 | 2.39 | 2.22 | 2,727,670.00 | 9.21 | 11.12 | 12.57 | 16.46 | 64.64 | 60.32 | 12.61 | 14.96 | 1.56 | -- | 0.1651 | 7.59 | 7.74 | 15.75 | -23.51 | -- | 26.73 | -- |
| Indoco Remedies Ltd | 17.73bn | 320.40m | 28.04bn | 5.93k | 91.21 | 2.57 | 20.57 | 1.58 | 3.34 | 3.34 | 175.26 | 118.23 | 0.8194 | 1.52 | 4.51 | 2,989,727.00 | 1.36 | 6.88 | 1.99 | 9.85 | 68.34 | 65.59 | 1.66 | 6.93 | 0.8142 | 1.71 | 0.4339 | 14.02 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
Data as of Nov 22 2024. Currency figures normalised to SMS Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
2.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 31 Oct 2024 | 2.15m | 2.54% |
| American Century Investment Management, Inc.as of 07 Nov 2024 | 881.00 | 0.00% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Oct 2024 | 655.00 | 0.00% |
| Bandhan AMC Ltd.as of 31 Oct 2024 | 404.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
